{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:29:50Z","timestamp":1790011790213,"version":"4.0.1"},"publisher-location":"Chichester, UK","reference-count":109,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd001747.pub2","type":"reference-entry","created":{"date-parts":[[2004,10,14]],"date-time":"2004-10-14T07:09:48Z","timestamp":1097737788000},"source":"Crossref","is-referenced-by-count":24,"title":["Galantamine for Alzheimer's disease"],"prefix":"10.1002","author":[{"given":"C","family":"Loy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,10,18]]},"reference":[{"key":"10.1002\/14651858.CD001747.pub2-BIB1|cit1","first-page":"661","article-title":"Galanthamine hydrobromide: Interim results of a group comparative, placebo-controlled study of efficacy and safety in patients with a diagnosis of senile dementia of the Alzheimer Type","volume-title":"Alzheimer's Disease: Biology, Diagnosis and Therapeutics","author":"Wilcock","year":"1997"},{"issue":"9","key":"10.1002\/14651858.CD001747.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/gps.409","article-title":"Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease","volume":"16","author":"Wilkinson","year":"2001","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD001747.pub2-BIB3|cit3","unstructured":"Kristensen M Richardson A Van Osselaer N Vangeneugden T Morrison S Fleet D Lilienfeld S Truyen L Parys W A Europan multicentre placebo-controlled trial to determine the safety and efficacy of galantamine hydrobromide 40mg\/d (32mg\/d GAL bas, tid dose regimen) in patients diagnosed with Alzheimer-type dementia (GAL 95-05) Janssen Research Foundation 1997"},{"key":"10.1002\/14651858.CD001747.pub2-BIB4|cit4","series-title":"Conference Proceedings World Alzheimer Congress; 9-13 July, 2000, Washington","article-title":"GALANTAMINE ALLEVIATES CAREGIVER BURDEN IN ALZHEIMER'S DISEASE: A 6-MONTH PLACEBO-CONTROLLED STUDY","author":"Wilcock","year":"2000"},{"issue":"7278","key":"10.1002\/14651858.CD001747.pub2-BIB5|cit5","first-page":"90","article-title":"Erratum: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial (British Medical Journal (December 9)(1445-1449))","volume":"322","author":"Wilcock","year":"2001","journal-title":"BR-MED-J: British-Medical-Journal"},{"key":"10.1002\/14651858.CD001747.pub2-BIB6|cit6","first-page":"1","article-title":"Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: a multicentre randomised controlled trial","volume":"321","year":"2000","journal-title":"British Medical Journal"},{"issue":"5","key":"10.1002\/14651858.CD001747.pub2-BIB7|cit7","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/jnnp.71.5.589","article-title":"Effects of a flexible galantamine dose in Alzheimer's disease: a randomized, controlled trial","volume":"71","year":"2001","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD001747.pub2-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0140-6736(02)08267-3","article-title":"Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial","volume":"359","author":"Erkinjuntti","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001747.pub2-BIB9|cit9","unstructured":"Erkinjuntti T Kurz A Gauthier S Bullock R Lilienfeld S Damaraju CV The safety and efficacy of Galantamine in the treatment of vascular and mixed dementia (Double-blind part only). (GAL-INT-6) Johnson and Johnson Pharmaceutical Research & Development"},{"issue":"12","key":"10.1002\/14651858.CD001747.pub2-BIB10|cit10","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1212\/WNL.54.12.2261","article-title":"Galantamine in AD: A 6-month randomized placebo-controlled trial with a 6-month extension","volume":"54","year":"2000","journal-title":"Neurology"},{"issue":"12","key":"10.1002\/14651858.CD001747.pub2-BIB11|cit11","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1212\/WNL.54.12.2269","article-title":"A 5-month, randomized, placebo-controlled trial of galamtine in AD","volume":"54","year":"2000","journal-title":"Neurology"},{"issue":"3S","key":"10.1002\/14651858.CD001747.pub2-BIB12|cit12","first-page":"130S","article-title":"Galantamine, a selective non-toxic acetylcholinesterase inhibitor is significantly superior over placebo in treatment of SDAT","volume":"10","author":"Kewitz","year":"1994","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1002\/14651858.CD001747.pub2-BIB13|cit13","first-page":"569","article-title":"New Alzheimer's drug is first therapy to show efficacy in vascular dementia","volume":"36","author":"Anon","year":"2001","journal-title":"Formulary"},{"issue":"7153","key":"10.1002\/14651858.CD001747.pub2-BIB14|cit14","first-page":"842","article-title":"Galantamine effective in treating dementia in patients with cerebrovascular disease","volume":"266","author":"Anon","year":"2001","journal-title":"Pharmaceutical Journal"},{"key":"10.1002\/14651858.CD001747.pub2-BIB15|cit15","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/clpt.1991.159","article-title":"Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition","volume":"50","author":"Bickel","year":"1991","journal-title":"Clin Pharmacol Ther"},{"key":"10.1002\/14651858.CD001747.pub2-BIB16|cit16","series-title":"Third International Springfield Symposium on Advances in Alzheimer's Therapy","first-page":"114","article-title":"Evaluation of P11012 and P11149 for the treatment of Alzheimer's disease","author":"Bores"},{"issue":"1","key":"10.1002\/14651858.CD001747.pub2-BIB17|cit17","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2165\/00002512-199609010-00007","article-title":"Galanthamine","volume":"9","author":"Brodaty","year":"1996","journal-title":"Drugs and Aging"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001747.pub2-BIB18|cit18","first-page":"S59","article-title":"Galantamine shows promising results in alzheimer's disease with cerebrovascular components and probable vascular dementia (preliminary results)","volume":"187","author":"Bullock","year":"2001","journal-title":"Journal of Neuroscience"},{"key":"10.1002\/14651858.CD001747.pub2-BIB19|cit19","series-title":"Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20-25, Stockholm, Sweden","first-page":"Abstract No 428","article-title":"Galantamine improves behaviour and relieves caregiver distress in Alzheimer's disease (AD), vascular dementia and AD with cerebrovascular disease","author":"Burke","year":"2002"},{"issue":"1","key":"10.1002\/14651858.CD001747.pub2-BIB20|cit20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2377-2-6","article-title":"To what degree does cognitive impairment in Alzheimer's disease predict dependence of patients on caregivers?","volume":"2","author":"Caro","year":"2002","journal-title":"BMC neurology [electronic resource]"},{"issue":"1","key":"10.1002\/14651858.CD001747.pub2-BIB21|cit21","first-page":"i","article-title":"Clinical and cost effectiveness of donepezil rivastigmine and galantamine for Alzheimer's disease a rapid and systematic review","volume":"5","author":"Clegg","year":"2001","journal-title":"Health Technology Assessment"},{"issue":"3","key":"10.1002\/14651858.CD001747.pub2-BIB22|cit22","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1017\/S026646230200034X","article-title":"Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease: a systematic review","volume":"18","author":"Clegg","year":"2002","journal-title":"International Journal of Technology Assessment in Health Care"},{"issue":"3","key":"10.1002\/14651858.CD001747.pub2-BIB23|cit23","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1742-1241.2003.tb10467.x","article-title":"Galantamine: a review of its use in Alzheimer's disease and vascular dementia","volume":"57","author":"Corey","year":"2003","journal-title":"International Journal of Clinical Practice"},{"issue":"3","key":"10.1002\/14651858.CD001747.pub2-BIB24|cit24","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0006-3223(00)01101-X","article-title":"Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: Effects on the course of Alzheimer's disease","volume":"49","author":"Coyle","year":"2001","journal-title":"Biological Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD001747.pub2-BIB25|cit25","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1176\/appi.ajgp.11.2.131","article-title":"Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations","volume":"11","author":"Cummings","year":"2003","journal-title":"American journal of geriatric psychiatry official journal of the American Association for Geriatric Psychiatry, The"},{"issue":"3","key":"10.1002\/14651858.CD001747.pub2-BIB26|cit26","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1176\/appi.ajp.161.3.532","article-title":"Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease","volume":"161","author":"Cummings","year":"2004","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001747.pub2-BIB27|cit27","first-page":"59","article-title":"Galanthamine treatment in Alzheimer's disease","volume":"33","author":"Dal","year":"1991","journal-title":"J Neurol Transm Suppl"},{"issue":"9344","key":"10.1002\/14651858.CD001747.pub2-BIB28|cit28","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(02)11451-6","article-title":"\"Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial\": Reply","volume":"360","author":"Erkinjuntti","year":"2002","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD001747.pub2-BIB29|cit29","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1046\/j.1468-1331.2002.04455.x","article-title":"Broad therapeutic benefits in patients with probable vascular dementia or Alzheimer's disease with cerebrovascular disease after treatment with galantamine","volume":"9","author":"Erkinjuntti","year":"2002","journal-title":"European Journal of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD001747.pub2-BIB30|cit30","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0149-2918(03)80168-6","article-title":"An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia","volume":"25","author":"Erkinjuntti","year":"2003","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD001747.pub2-BIB31|cit31","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2165\/00002512-199609010-00006","article-title":"Galanthamine","volume":"9","author":"Fulton","year":"1996","journal-title":"Drugs Aging"},{"issue":"7","key":"10.1002\/14651858.CD001747.pub2-BIB32|cit32","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/j.1532-5415.2004.52303.x","article-title":"Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease","volume":"52","author":"Galasko","year":"2004","journal-title":"Journal of the American Geriatrics Society"},{"issue":"6","key":"10.1002\/14651858.CD001747.pub2-BIB33|cit33","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s11910-002-0036-z","article-title":"Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial","volume":"2","author":"Kertesz","year":"2002","journal-title":"Current Neurology & Neuroscience Reports"},{"key":"10.1002\/14651858.CD001747.pub2-BIB34|cit34","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/978-1-4615-8149-9_25","article-title":"Galanthamine in Alzheimer's disease","volume-title":"Alzheimer's disease: Therapeutic strategies","author":"Kewitz","year":"1994"},{"issue":"4","key":"10.1002\/14651858.CD001747.pub2-BIB35|cit35","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1358\/dot.1997.33.4.425052","article-title":"Pharmacokinetics and metabolism of galanthamine","volume":"33","author":"Kewtiz","year":"1997","journal-title":"Drugs of Today"},{"key":"10.1002\/14651858.CD001747.pub2-BIB36|cit36","series-title":"Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23-26, San Francisco","article-title":"Galantamine alleviates caregiver burden in Alzheimer's disease","author":"Lilienfeld","year":"2001"},{"key":"10.1002\/14651858.CD001747.pub2-BIB37|cit37","series-title":"Proceedings of the 7th International Geneva\/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3-6, Geneva","first-page":"214","article-title":"Long-term cognitive benefits of galantamine in alzheimer disease using a responder analysis at 18.5 months","author":"Lyketsos","year":"2002"},{"key":"10.1002\/14651858.CD001747.pub2-BIB38|cit38","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/(SICI)1099-1166(199809)13:9<625::AID-GPS835>3.0.CO;2-2","article-title":"Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease","volume":"13","author":"MacGowan","year":"1998","journal-title":"Int J Geriat Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD001747.pub2-BIB39|cit39","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11910-002-0062-x","article-title":"Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial","volume":"2","author":"Marder","year":"2002","journal-title":"Current Neurology and Neuroscience Reports"},{"issue":"5","key":"10.1002\/14651858.CD001747.pub2-BIB40|cit40","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1093\/sleep\/26.5.602","article-title":"Sleep-related outcomes in persons with mild to moderate Alzheimer disease in a placebo-controlled trial of galantamine","volume":"26","author":"Markowitz","year":"2003","journal-title":"Sleep"},{"key":"10.1002\/14651858.CD001747.pub2-BIB41|cit41","series-title":"Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology (ACNP); 2000 Dec 10-14, San Juan, Puerto Rico","article-title":"Efficacy of galantamine in patients with alzheimer's disease (AD) with previous exposure to cholinesterase inhibitors","author":"Mintzer","year":"2000"},{"key":"10.1002\/14651858.CD001747.pub2-BIB42|cit42","series-title":"Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23-26, San Francisco","article-title":"Galantamine provides cognitive and functional benefits over 12 months in patients with Alzheimer's disease","author":"Mintzer","year":"2001"},{"issue":"9344","key":"10.1002\/14651858.CD001747.pub2-BIB43|cit43","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S0140-6736(02)11450-4","article-title":"\"Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial\": Comment","volume":"360","author":"Moretti","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001747.pub2-BIB44|cit44","series-title":"Proceedings of the 7th International Geneva\/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3-6, Geneva","first-page":"220","article-title":"Cognitive benefits of long-term, continuous galantamine treatment in patients with alzheimer disease","author":"Morris","year":"2002"},{"issue":"4","key":"10.1002\/14651858.CD001747.pub2-BIB45|cit45","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1358\/dot.1997.33.4.425051","article-title":"Preclinical studies with galanthamine","volume":"3","author":"Mucke","year":"1997","journal-title":"Drugs of Today"},{"key":"10.1002\/14651858.CD001747.pub2-BIB46|cit46","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2165\/00002018-199819060-00004","article-title":"Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology","volume":"19","author":"Nordberg","year":"1998","journal-title":"Drug Safety"},{"key":"10.1002\/14651858.CD001747.pub2-BIB47|cit47","first-page":"30","article-title":"Treatment of the psychogenic form of sexual asthenia with Nivalin (Bulgarian)","volume":"25","author":"Paskov","year":"1974","journal-title":"Savrmed"},{"key":"10.1002\/14651858.CD001747.pub2-BIB48|cit48","series-title":"Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20-25, Stockholm, Sweden","first-page":"Abstract No 342","article-title":"A 6 month open label study of the efficacy and tolerability of galantamine in patients with Alzheimers disease (AD)","author":"Patterson","year":"2002"},{"issue":"6","key":"10.1002\/14651858.CD001747.pub2-BIB49|cit49","first-page":"307","article-title":"[Observation of effect on Alzheimer disease treated by Galanthamine hydrobromide capules]","volume":"14","author":"Ping","year":"2000","journal-title":"Practical Geriatrics"},{"key":"10.1002\/14651858.CD001747.pub2-BIB50|cit50","series-title":"Canadian Journal of Neurological Sciences","first-page":"S177","article-title":"Galanthamine treatment in Alzheimer's Disease: a preliminary evaluation of forty patients of forty patients","author":"Rainer","year":"1993"},{"key":"10.1002\/14651858.CD001747.pub2-BIB51|cit51","series-title":"Neuropsychopharmacology","first-page":"215S","article-title":"Galanthamine treatment in Alzheimer's disease - The identification of responders","author":"Rainer","year":"1994"},{"key":"10.1002\/14651858.CD001747.pub2-BIB52|cit52","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1358\/dot.1997.33.4.425053","article-title":"Clinical studies with galantamine","volume":"33","author":"Rainer","year":"1997","journal-title":"Drugs of Today"},{"issue":"2","key":"10.1002\/14651858.CD001747.pub2-BIB53|cit53","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/00023210-199707020-00001","article-title":"Galanthamine in Alzheimer's disease. A new alternative to tacrine?","volume":"7","author":"Rainer","year":"1997","journal-title":"CNS Drugs"},{"issue":"11","key":"10.1002\/14651858.CD001747.pub2-BIB54|cit54","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s007020100009","article-title":"Cognitive relapse after discontinuation of drug therapy in Alzheimer's disease: cholinesterase inhibitors versus nootropics","volume":"108","author":"Rainer","year":"2001","journal-title":"Journal of neural transmission"},{"key":"10.1002\/14651858.CD001747.pub2-BIB55|cit55","series-title":"Proceedings of the 6th International Stockholm\/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5-8, Stockholm, Sweden","first-page":"225","article-title":"Galantamine produces long term cognitive and functional in patients with Alzheimer's disease","author":"Raskind","year":"2000"},{"key":"10.1002\/14651858.CD001747.pub2-BIB56|cit56","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0165-1781(94)90013-2","article-title":"Influence of the cholinesterase inhibitor galanthamine hydrobromide on normal sleep","volume":"51","author":"Riemann","year":"1994","journal-title":"Psychiatry Res"},{"issue":"suppl 1","key":"10.1002\/14651858.CD001747.pub2-BIB57|cit57","article-title":"Cholinergic neurotransmission, REM sleep and depression","volume":"38","author":"Riemann","year":"1994","journal-title":"J Psychosom Res"},{"issue":"10","key":"10.1002\/14651858.CD001747.pub2-BIB58|cit58","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/gps.1000","article-title":"The effects of galantamine treatment on caregiver time in Alzheimer's disease","volume":"18","author":"Sano","year":"2003","journal-title":"International journal of geriatric psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD001747.pub2-BIB59|cit59","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2165\/00003495-200060050-00008","article-title":"Galantamine: a review of its use in Alzheimer's disease","volume":"60","author":"Scott","year":"2000","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD001747.pub2-BIB60|cit60","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1300\/J092v02n02_04","article-title":"Trial of a selective acetylcholinesterase inhibitor, galanthamine hydrobromide, in the treatment of chronic fatigue syndrome","volume":"2","author":"Snorrason","year":"1996","journal-title":"J Chronic Fatigue Syndr"},{"key":"10.1002\/14651858.CD001747.pub2-BIB61|cit61","series-title":"unknown","article-title":"Discontinuation of Acetylcholinesterase-Inhibitors in Alzheimer's disease and itrs effects on cognitive functioning","author":"Steiger-Baechler","year":"2002"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001747.pub2-BIB62|cit62","first-page":"A415","article-title":"The efficacy and tolerability of galantamine in alzheimer's disease a 5 month placebo controlled study with slow dose escalation","volume":"54","author":"Tariot","year":"2000","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001747.pub2-BIB63|cit63","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/0024-3205(90)90429-U","article-title":"Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo","volume":"46","author":"Thomsen","year":"1990","journal-title":"Life Sci"},{"key":"10.1002\/14651858.CD001747.pub2-BIB64|cit64","first-page":"46","article-title":"Galantamine hydrobromide in a long-term treatment of Alzheimer's disease","volume":"1","author":"Thomsen","year":"1990","journal-title":"Dementia"},{"key":"10.1002\/14651858.CD001747.pub2-BIB65|cit65","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/BF00316106","article-title":"Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans","volume":"39","author":"Thomsen","year":"1990","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1002\/14651858.CD001747.pub2-BIB66|cit66","series-title":"Proceedings of the Sixth International Stockholm\/Springfield Symposium on Advances in Alzheimer's Disease","first-page":"156","article-title":"Galantamine-New Clinical Studies","author":"Truyen","year":"2000"},{"key":"10.1002\/14651858.CD001747.pub2-BIB67|cit67","series-title":"Proceedings of the Sixth International Stockholm\/Springfield Symposium on Advances in Alzheimer's Disease","first-page":"157","article-title":"Clinical implications for galantamine's nicotinic receptor modulation","author":"Truyen","year":"2000"},{"key":"10.1002\/14651858.CD001747.pub2-BIB68|cit68","series-title":"The second kuopio Alzheimer symposium, Kuopio Music Centre, Kuopio, Finland, March 13-15, 2001","first-page":"42","article-title":"Galantamine clinical implications for nicotinic receptor modulation","author":"Truyen","year":"2001"},{"issue":"9344","key":"10.1002\/14651858.CD001747.pub2-BIB69|cit69","first-page":"1512","article-title":"Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial: comment","volume":"360","author":"Gool","year":"2002","journal-title":"Lancet"},{"issue":"51-52","key":"10.1002\/14651858.CD001747.pub2-BIB70|cit70","first-page":"31","article-title":"Acetylcholinesterase inhibitors: Galanthamine in Alzheimer's Dementia","volume":"137","author":"Wasielewski","year":"1997","journal-title":"Deutsche Apotheker Zeitung"},{"key":"10.1002\/14651858.CD001747.pub2-BIB71|cit71","first-page":"781","article-title":"Galanthamine and the treatment of Alzheimer's disease","volume":"8","author":"Wilcock","year":"1993","journal-title":"Int J Geriat Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD001747.pub2-BIB72|cit72","first-page":"16","article-title":"Reminyl (galantamine) alleviates caregiver burden in alzheimer's disease in two 6 month studies","volume":"1","author":"Wilcock","year":"2000","journal-title":"Clinical Neuropsychological Assessment"},{"issue":"6","key":"10.1002\/14651858.CD001747.pub2-BIB73|cit73","first-page":"43","article-title":"Long term cognitive and functional benefits of reminyl (galantamine ) in patients with alzheimer's disease","volume":"1","author":"Wilcock","year":"2000","journal-title":"Clinical Neuropsychological Assessment"},{"key":"10.1002\/14651858.CD001747.pub2-BIB74|cit74","series-title":"Proceedings of the 6th International Stockholm\/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5-8, Stockholm, Sweden","first-page":"233","article-title":"Galantamine improves activities of daily living in patients with alzheimer's disease: A 3 month placebo-controlled study","author":"Wilkinson","year":"2000"},{"issue":"5","key":"10.1002\/14651858.CD001747.pub2-BIB75|cit75","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/ajhp\/60.5.446","article-title":"Galantamine hydrobromide: an agent for Alzheimer's disease","volume":"60","author":"Zarotsky","year":"2003","journal-title":"American journal of health system pharmacy AJHP official journal of the American Society of Health System Pharmacists"},{"key":"10.1002\/14651858.CD001747.pub2-BIB76|cit76","unstructured":"Double blind, Randomised controlled trial comparing different galantamine dosing reigms Ongoing study"},{"key":"10.1002\/14651858.CD001747.pub2-BIB77|cit77","unstructured":"Not reported Ongoing study"},{"key":"10.1002\/14651858.CD001747.pub2-BIB78|cit78","unstructured":"The safety and efficacy of Galanthamine in the treatment of vascular and mixed dementia Ongoing study"},{"key":"10.1002\/14651858.CD001747.pub2-BIB79|cit79","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"1987"},{"issue":"2","key":"10.1002\/14651858.CD001747.pub2-BIB80|cit80","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000067974","article-title":"Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months","volume":"15","author":"Blesa","year":"2003","journal-title":"Dementia and geriatric cognitive disorders"},{"key":"10.1002\/14651858.CD001747.pub2-BIB81|cit81","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1056\/NEJM198312013092204","article-title":"Bias in Treatment Assignment in Controlled Clinical Trials","volume":"309","author":"Chalmers","year":"1983","journal-title":"N Eng J Med"},{"issue":"1","key":"10.1002\/14651858.CD001747.pub2-BIB82|cit82","first-page":"i","article-title":"Clinical and cost effectiveness of donepezil rivastigmine and galantamine for Alzheimer's disease a rapid and systematic review","volume":"5","author":"Clegg","year":"2001","journal-title":"Health Technology Assessment"},{"issue":"12","key":"10.1002\/14651858.CD001747.pub2-BIB83|cit83","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001747.pub2-BIB84|cit84","volume-title":"Treatment of early breast cancer: Worldwide evidence 1985-1990","year":"1990"},{"key":"10.1002\/14651858.CD001747.pub2-BIB85|cit85","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0140-6736(02)08267-3","article-title":"Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial","volume":"359","author":"Erkinjuntti","year":"2002","journal-title":"The Lancet"},{"key":"10.1002\/14651858.CD001747.pub2-BIB86|cit86","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"Mini-mental State. A practical method for grading the cognitive status of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"Journal of Psychiatry Research"},{"key":"10.1002\/14651858.CD001747.pub2-BIB87|cit87","unstructured":"Gutierrez R Kershaw P Wessel T Pontecorvo M Shnaidman M Chang S Safety and efficacy of galantamine during its withdrawal in the treatment of Alzheimer's Disease Jansseen Research Foundation 1998"},{"key":"10.1002\/14651858.CD001747.pub2-BIB88|cit88","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/00002093-199700112-00005","article-title":"An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study","volume":"11","author":"Galasko","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"5","key":"10.1002\/14651858.CD001747.pub2-BIB89|cit89","doi-asserted-by":"crossref","first-page":"471","DOI":"10.5014\/ajot.53.5.471","article-title":"Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia","volume":"53","author":"Gelinas","year":"1999","journal-title":"Am J Occup Ther"},{"issue":"6","key":"10.1002\/14651858.CD001747.pub2-BIB90|cit90","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1212\/WNL.57.6.972","article-title":"Assessment of health economics in Alzheimer's disease AHEAD galantamine treatment in canada","volume":"57","year":"2001","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001747.pub2-BIB91|cit91","first-page":"218","article-title":"Clinical Global Impressions (CGI)","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD001747.pub2-BIB92|cit92","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0163-7258(95)02002-0","article-title":"The pharmacology of galanthamine and its analogues","volume":"68","author":"Harvey","year":"1995","journal-title":"Pharmac. Ther"},{"key":"10.1002\/14651858.CD001747.pub2-BIB93|cit93","volume-title":"World Health Organization","year":"1992"},{"issue":"1-3","key":"10.1002\/14651858.CD001747.pub2-BIB94|cit94","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3109\/10799899709036592","article-title":"Allosteric modulation of Torpedo nicotinic acetylcholine receptor ion channel activity by noncompetitive agonists","volume":"17","author":"Maelicke","year":"1997","journal-title":"Journal-of-receptor-and-signal-transduction-research"},{"key":"10.1002\/14651858.CD001747.pub2-BIB95|cit95","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical Diagnosis of Alzheimer\u2019s Disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease","volume":"4","author":"McKhann","year":"1984","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD001747.pub2-BIB96|cit96","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/S0149-2918(03)80171-6","article-title":"Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the united states","volume":"25","author":"Migliaccio-Walle","year":"2003","journal-title":"Clinical Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD001747.pub2-BIB97|cit97","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/gps.826","article-title":"The efficacy of galantamine in the treatment of Alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure","volume":"18","author":"Mintzer","year":"2003","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"9344","key":"10.1002\/14651858.CD001747.pub2-BIB98|cit98","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S0140-6736(02)11450-4","article-title":"\"Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial\": Comment","volume":"360","author":"Moretti","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001747.pub2-BIB99|cit99","article-title":"Cochrane Collaboration Handbook","volume-title":"Cochrane Collaboration Handbook [updated 9 December 1996] Available in The Cochrane Library [database on disk and CDROM], Issue 1","author":"Mulrow","year":"1997"},{"key":"10.1002\/14651858.CD001747.pub2-BIB100|cit100","first-page":"767","article-title":"Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetycholinesterase","volume":"274","author":"Pacheco","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1002\/14651858.CD001747.pub2-BIB101|cit101","first-page":"939","article-title":"A new rating scale for Alzheimer's disease","volume":"141","author":"Rosen","year":"1984","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001747.pub2-BIB102|cit102","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1097\/00002093-199700112-00004","article-title":"Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC)","volume":"11","author":"Schneider","year":"1997","journal-title":"Alzheimer's Disease and Associated Disorders"},{"key":"10.1002\/14651858.CD001747.pub2-BIB103|cit103","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.273.5.408","article-title":"Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD001747.pub2-BIB104|cit104","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0091-3057(88)90325-5","article-title":"A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice","volume":"31","author":"Sweeney","year":"1988","journal-title":"Pharmacology Biochemistry and Behavior"},{"key":"10.1002\/14651858.CD001747.pub2-BIB105|cit105","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1007\/BF00785549","article-title":"Interaction of reversible inhibitors with catalytic centres and allosteric site of cholinesterases","volume":"82","author":"Tonkopii","year":"1976","journal-title":"Bull. Exp. Bio. Med"},{"issue":"9344","key":"10.1002\/14651858.CD001747.pub2-BIB106|cit106","first-page":"1512","article-title":"Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial: comment","volume":"360","author":"Gool","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001747.pub2-BIB107|cit107","first-page":"562","article-title":"GALANTAMINE ALLEVIATES CAREGIVER BURDEN IN ALZHEIMER\u00a2S DISEASE: A 6-MONTH PLACEBO-CONTROLLED STUDY","volume":"15","author":"Wilcock","year":"2000","journal-title":"Conference Proceedings World Alzheimer Congress; 9-13 July, 2000; Washington"},{"issue":"7278","key":"10.1002\/14651858.CD001747.pub2-BIB108|cit108","first-page":"90","article-title":"Erratum: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial (British Medical Journal (December 9)(1445-1449))","volume":"322","author":"Wilcock","year":"2001","journal-title":"BR-MED-J: British-Medical-Journal"},{"issue":"7","key":"10.1002\/14651858.CD001747.pub2-BIB109|cit109","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1742-1241.2002.tb11310.x","article-title":"Galantamine provides broad benefits in patients with 'advanced moderate' Alzheimer's disease (MMSE < or = 12) for up to six months","volume":"56","author":"Wilkinson","year":"2002","journal-title":"International Journal of Clinical Practice"}],"updated-by":[{"DOI":"10.1002\/14651858.cd001747.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2006,1,25]],"date-time":"2006-01-25T00:00:00Z","timestamp":1138147200000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD001747.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T15:21:19Z","timestamp":1682781679000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD001747.pub2"}},"subtitle":[],"editor":[{"given":"Clement","family":"Loy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2004,10,18]]},"references-count":109,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001747.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD001747.pub3","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2004,10,18]]}}}